Study of Artery Conditions of 'At-risk' Asian People Not on Lipid-lowering Drugs
CIMT
Prevalence of Atherosclerotic Disease in Asian Subjects Not on Lipid-lowering Agents, But With at Least Two CVD Risk Factors
1 other identifier
interventional
2,609
9 countries
19
Brief Summary
The purpose of this study is to obtain the distribution of measurements of the intima media thickness of carotid arteries in people with high cardiovascular risk.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable
Started Oct 2009
Shorter than P25 for not_applicable
19 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
August 25, 2009
CompletedFirst Posted
Study publicly available on registry
September 3, 2009
CompletedStudy Start
First participant enrolled
October 1, 2009
CompletedPrimary Completion
Last participant's last visit for primary outcome
August 1, 2010
CompletedStudy Completion
Last participant's last visit for all outcomes
August 1, 2010
CompletedSeptember 24, 2010
September 1, 2010
10 months
August 25, 2009
September 22, 2010
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Measurement of Carotid Intima Media Thickness of people with high risk of cardiovascular disease but not on lipid lowering drugs
IIMT measurements taken only once, either on Visit 1 or Visit 2 (time gap between V1 and V2 should be less than 3 months)
Secondary Outcomes (1)
Lipid profile of people with high risk of cardiovascular disease but not on lipid lowering drugs
Blood sampling only once, either on Visit 1 or Visit 2 (time gap between V1 and V2 should be less than 3 months)
Study Arms (1)
1
EXPERIMENTALInterventions
one time, radiological procedure on both sides of the neck
Eligibility Criteria
You may qualify if:
- Provision of signed informed consent.
- Patients with at least two CVD risk factors but not on lipid-lowering agents
You may not qualify if:
- Subjects with CHD, any conditions that may affect hs-CRP levels.
- Subjects on any lipid-lowering drug treatment within the last 3 months prior study entry.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- AstraZenecalead
Study Sites (19)
Research Site
Beijing, Beijing Municipality, China
Research Site
Shanghai, Shanghai Municipality, China
Research Site
Gūrgaon, India
Research Site
Jaipur, India
Research Site
Meerut, India
Research Site
Denpasar, Bali, Indonesia
Research Site
Bandung-Jawa, Barat, Indonesia
Research Site
Semarang-Jawa, Tengah, Indonesia
Research Site
Surabaya, Timur, Indonesia
Research Site
Kuching, Sarawak, Malaysia
Research Site
Manila, Manila, Philippines
Research Site
Quezon City, Philippines
Research Site
Seoul, Seoul, South Korea
Research Site
Kaohsiung, Taipei, Taiwan
Research Site
Shilin, Taipei, Taiwan
Research Site
Taoyuan, Taipei, Taiwan
Research Site
Patumwan, Bangkok, Thailand
Research Site
Hanoi, Hanoi, Vietnam
Research Site
Ho Chi Minh City, Ho Chi Min, Vietnam
MeSH Terms
Conditions
Interventions
Intervention Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Guy Yeoman, MD
Asia Pacific Regional Office, AstraZeneca Singapore Pte Ltd 8 Wilkie Road, #07-01 Wilkie Edge, Singapore 228095
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Purpose
- SCREENING
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- INDUSTRY
Study Record Dates
First Submitted
August 25, 2009
First Posted
September 3, 2009
Study Start
October 1, 2009
Primary Completion
August 1, 2010
Study Completion
August 1, 2010
Last Updated
September 24, 2010
Record last verified: 2010-09